PharmaEssentia Corporation
6446
Rangering i aksjer
#1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aksjekurs
$36.89
Markedsverdi
$15.25B
Endring (1 dag)
-1.28%
Endring (1 år)
144.12%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Antall utestående aksjer for PharmaEssentia Corporation (6446)
Antall utestående aksjer per June 2026: 504.54M
Ifølge PharmaEssentia Corporation sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 504.54M. Ved slutten av December 2023 hadde selskapet 357.63M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for PharmaEssentia Corporation (6446) fra 2010 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 504.54M | 39.70% |
| 2024 | 361.15M | 0.98% |
| 2023 | 357.63M | 13.47% |
| 2022 | 315.19M | 9.24% |
| 2021 | 288.52M | 6.05% |
| 2020 | 272.06M | 11.95% |
| 2019 | 243.02M | -2.49% |
| 2018 | 249.23M | 0.35% |
| 2017 | 248.36M | 6.59% |
| 2016 | 233.00M | 7.71% |
| 2015 | 216.33M | 0.61% |
| 2014 | 215.01M | 7.64% |
| 2013 | 199.75M | 37.81% |
| 2012 | 144.95M | 4.85% |
| 2011 | 138.25M | 0.00% |
| 2010 | 138.25M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 375.55% |
IN
|
